tenofovir alafenamide

01/01/2022 - "Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply."
01/01/2022 - "Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B."
06/24/2022 - "One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study."
01/01/2022 - "HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks."
10/26/2023 - "Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study."

10/28/2022 - "We demonstrated complete protection against vaginal SHIV infection with two implants releasing a total of 0.7 mg of tenofovir alafenamide per day. "
10/28/2022 - "Efficacy against vaginal simian-HIV (SHIV) infection was investigated in six pigtailed macaques that received two tenofovir alafenamide implants (0.35 mg/day), one in each arm, for a total release rate of tenofovir alafenamide at 0.7 mg/day. "
07/01/2023 - "Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection."
10/28/2022 - "All macaques with tenofovir alafenamide implants were protected against vaginal SHIV infection. "
01/01/2021 - "SIGNIFICANCE STATEMENT: Identification of a small molecule that inhibits bitter taste from tenofovir alafenamide may increase the compliance in treating children with human immunodeficiency virus infections."

11/02/2021 - "Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study."
02/16/2021 - "Hepatitis B viral load was 72100000 IU/mL. The patient started tenofovir alafenamide fumigate 25 mg daily. "
11/01/2016 - "Tenofovir alafenamide for hepatitis B: evolution or revolution?"
03/01/2015 - "Tenofovir alafenamide 25 mg has been selected for further hepatitis B clinical development."
01/01/2020 - "Tenofovir alafenamide (TAF) has been introduced as a novel treatment option and new principles regarding indication and duration of treatment and characterization of hepatitis B have been gradually introduced which justifies an update of the previous guidelines from 2007. "

10/28/2022 - "Improved tenofovir alafenamide implants that are safe and maintain high efficacy have the potential to provide long-lasting protection against vaginal HIV infection."
01/01/2020 - "We describe the in vitro and in vivo evaluation of a subcutaneous reservoir implant delivering tenofovir alafenamide hemifumarate (TAF) for the prevention of HIV infection. "
12/01/2019 - "The possibility that TFV-DP accumulation and retention in epithelial cells and fibroblasts may alter TFV availability and protection of CD4+ T cells against HIV infection, prompted us to evaluate TFV and/or Tenofovir alafenamide (TAF) release from FRT cells. "
06/27/2015 - "Tenofovir alafenamide for HIV infection: is less more?"
01/01/2023 - "To compare the impact of tenofovir alafenamide (TAF) on the slope of the estimated glomerular filtration rate (eGFR) with that of abacavir in Japanese patients living with HIV infection. "

01/01/2020 - "Our findings suggest that switching to tenofovir alafenamide was effective for HBV suppression and the improvement in renal function for patients with chronic kidney disease."
10/01/2016 - "Last, tenofovir alafenamide renal safety in patients with chronic kidney disease has not been studied in any randomized clinical trial. "
04/01/2022 - "Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease."
12/01/2016 - "This review summarizes the major epidemiologic studies of kidney diseases in HIV-infected patients, discusses novel approaches that may potentially limit nephrotoxicity such as the use of tenofovir alafenamide, and outlines current screening measures for early diagnosis of kidney dysfunction or tubular damage, and for accurate detection of increased risk for acute or chronic kidney diseases."
01/01/2023 - "To characterize the usual range of tenofovir exposure in PLWH receiving tenofovir alafenamide, while assessing the impact of chronic kidney disease (CKD). "